Capital Analysts LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Analysts LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Hold	446	–	–	﹤0.01%	1105
2026 Q1	$25K	Hold	446	–	–	﹤0.01%	1077
2025 Q4	$27K	Hold	446	–	–	﹤0.01%	1043
2025 Q3	$24K	Hold	446	–	–	﹤0.01%	1030
2025 Q2	$25K	Hold	446	–	–	﹤0.01%	956
2025 Q1	$32K	Sell	446 -71	-14%	-$4.78K	﹤0.01%	879
2024 Q4	$34K	Hold	517	–	–	﹤0.01%	827
2024 Q3	$36K	Sell	517 -243	-32%	-$20.3K	﹤0.01%	789
2024 Q2	$63K	Sell	760 -135	-15%	-$11.2K	﹤0.01%	659
2024 Q1	$78K	Hold	895	–	–	﹤0.01%	588
2023 Q4	$86K	Sell	895 -105	-11%	-$9.29K	﹤0.01%	555
2023 Q3	$88K	Buy	1,000 +121	+14%	+$10.8K	﹤0.01%	506
2023 Q2	$76K	Hold	879	–	–	﹤0.01%	515
2023 Q1	$85K	Hold	879	–	–	﹤0.01%	497
2022 Q4	$91K	Hold	879	–	–	0.01%	519
2022 Q3	$75K	Hold	879	–	–	0.01%	492
2022 Q2	$73K	Hold	879	–	–	0.01%	484
2022 Q1	$68K	Sell	879 -65	-7%	-$5.44K	﹤0.01%	504
2021 Q4	$83K	Buy	+944	New	+$77.9K	0.01%	480
2019 Q3	–	Sell	-25	Closed	-$2K	–	699
2019 Q2	$2K	Buy	+25	New	+$2.14K	﹤0.01%	628

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Capital Analysts LLC's BMRN Position: Q2 2026 in Review

Capital Analysts LLC held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 446 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1105.

Capital Analysts LLC first reported a position in BMRN in Q2 2019 and has held it in 20 quarters since. The position peaked at $91K in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Capital Analysts LLC held 446 shares of BioMarin Pharmaceuticals worth $26K as of Q2 2026.
Capital Analysts LLC left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1105 holding.
Capital Analysts LLC first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 20 quarters since.
Capital Analysts LLC's BioMarin Pharmaceuticals position peaked at $91K in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.